(Q34606050)

3 August 2017

1 reference

title

Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection (English)

1 reference

3 August 2017

Raymond Yost

1

1 reference

3 August 2017

Timothy R Pasquale

series ordinal

2

1 reference

3 August 2017

Eric G Sahloff

series ordinal

3

1 reference

3 August 2017

publication date

1 April 2009

1 reference

American Journal of Health-System Pharmacy

3 August 2017

published in

1 reference

3 August 2017

volume

66

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

715-726

1 reference

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

Identification of a major co-receptor for primary isolates of HIV-1

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

GlaxoSmithKline ends aplaviroc trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080206

31 March 2020

Identifiers

DOI

10.2146/AJHP080206

1 reference

3 August 2017

1 reference